Ditchcarbon
  • Customers
  1. Organizations
  2. Mitsubishi Tanabe Pharma
Public Profile
Pharmaceutical Preparation Manufacturing
JP
updated 10 days ago

Mitsubishi Tanabe Pharma

Company website

Mitsubishi Tanabe Pharma Corporation, often referred to as MTPC, is a prominent player in the global pharmaceutical industry, headquartered in Japan. Established in 1678, the company has evolved significantly, focusing on innovative drug development and therapeutic solutions primarily in the fields of neurology, immunology, and diabetes care. With a strong presence in Japan, North America, and Europe, Mitsubishi Tanabe Pharma is renowned for its unique core products, including treatments for multiple sclerosis and other chronic conditions. The company has achieved notable milestones, such as the successful launch of its flagship drug, which has positioned it as a leader in the biopharmaceutical market. Committed to advancing healthcare, Mitsubishi Tanabe Pharma continues to make significant contributions to patient well-being through its research and development initiatives.

DitchCarbon Score

How does Mitsubishi Tanabe Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

52

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Mitsubishi Tanabe Pharma's score of 52 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.

73%

Let us know if this data was useful to you

Mitsubishi Tanabe Pharma's reported carbon emissions

In 2023, Mitsubishi Tanabe Pharma reported total greenhouse gas emissions of approximately 740,900,000 kg CO2e. This figure includes Scope 1 emissions of about 18,700,000 kg CO2e, Scope 2 emissions of around 36,300,000 kg CO2e, and significant Scope 3 emissions totalling approximately 700,900,000 kg CO2e. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (approximately 682,200,000 kg CO2e) and capital goods (about 17,100,000 kg CO2e). Mitsubishi Tanabe Pharma has set ambitious climate commitments, aiming for a 45% reduction in Scope 1 and 2 emissions by 2030, compared to fiscal 2019 levels, with a long-term goal of achieving net-zero emissions by 2050. These targets encompass all domestic and overseas group companies and reflect the company's commitment to sustainability. The emissions data is cascaded from its parent company, Mitsubishi Tanabe Pharma Corporation, which also adheres to similar sustainability initiatives. The company has disclosed emissions data across all relevant scopes, demonstrating transparency in its environmental impact reporting.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20162017201820192020202120222023
Scope 1
35,400,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
71,800,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
000,000,000
-
000,000,000
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Mitsubishi Tanabe Pharma's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Mitsubishi Tanabe Pharma is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Mitsubishi Tanabe Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Moderna

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Johnson And Johnson

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Eisai

JP
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250808.9
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy